Clinical characteristics and molecular epidemiology of invasive Streptococcus agalactiae infections between 2007 and 2016 in Nara, Japan.
Adult
Aged
Aged, 80 and over
Antibiotic Prophylaxis
/ methods
Electrophoresis, Gel, Pulsed-Field
Female
Humans
Japan
/ epidemiology
Levofloxacin
/ therapeutic use
Male
Microbial Sensitivity Tests
Middle Aged
Molecular Epidemiology
Multilocus Sequence Typing
Serogroup
Serotyping
Streptococcal Infections
/ drug therapy
Streptococcus agalactiae
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
03
2020
accepted:
30
09
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Invasive Streptococcus agalactiae (GBS) infections are increasingly common among neonates and the elderly. Therefore, GBS surveillance for better antibiotic treatment and prophylaxis strategies are needed. We retrospectively evaluated the clinical aspects of invasive infections and the phenotypic and genetic diversity of infectious isolates from Nara, Japan, collected between 2007 and 2016, by using information from hospital records. GBS strains collected from the blood and cerebrospinal fluid cultures were evaluated for capsular types, multi-locus sequence typing (MLST), antibiotic susceptibility, antibiotics resistance gene, and pulsed-field gel electrophoresis. Forty GBS isolates (10 from children and 30 from adults) were analyzed, and the distribution of molecular serotype and allelic profiles varied between children and adults. We found the rates of early-onset disease in neonates with birth complications to be higher than that of previous reports, indicating that there could be relevance between complications at birth and early-onset disease. Standard antibiotic prophylaxis strategies may need to be reconsidered in patients with birth complications. In adults, the mean age of the patients was 68 years (male: 63%). Primary bacteremia was the most common source of infection. In the neonates, six had early-onset diseases and four had late-onset diseases. The most frequently identified strains were molecular serotype Ia ST23 (40%) and molecular serotype Ib ST10 (20%) in children and molecular serotype Ib ST10 (17%), molecular serotype VI ST1 (13%), and molecular serotype V ST1 (13%) in adults. Levofloxacin-resistant molecular serotype Ib strains and molecular serotypes V and VI ST1 were common causes of GBS infection in adults but were rarely found in children. Furthermore, pulsed-field gel electrophoresis in our study showed that specific clone isolates, that tend to have antibiotics resistance were widespread horizontally for a decade. Continuous surveillance and molecular investigation are warranted to identify the transmission route and improve antibiotic treatment strategies.
Identifiants
pubmed: 33075112
doi: 10.1371/journal.pone.0240590
pii: PONE-D-20-08051
pmc: PMC7571711
doi:
Substances chimiques
Levofloxacin
6GNT3Y5LMF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0240590Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist. BML Biomedical Laboratories R&D Center, Inc., provided support in the form of salaries for the author MO and SI, but did not have any additional role in the study design, data collection and analysis, decision to poublish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Jpn J Infect Dis. 2007 Feb;60(1):10-3
pubmed: 17314418
Am J Infect Control. 2018 Mar;46(3):e19-e24
pubmed: 29305279
N Engl J Med. 1993 Jun 24;328(25):1807-11
pubmed: 8502269
Antimicrob Agents Chemother. 2008 Aug;52(8):2890-7
pubmed: 18490507
BMC Infect Dis. 2014 Jun 12;14:323
pubmed: 24919844
J Microbiol Immunol Infect. 2016 Dec;49(6):902-909
pubmed: 25560254
J Clin Microbiol. 2003 Jun;41(6):2530-6
pubmed: 12791877
JAMA. 2008 May 7;299(17):2056-65
pubmed: 18460666
Am J Obstet Gynecol. 2000 Oct;183(4):859-62
pubmed: 11035326
J Infect Chemother. 2014 Aug;20(8):509-11
pubmed: 24880684
Sci Rep. 2019 Sep 19;9(1):13525
pubmed: 31537886
J Antimicrob Chemother. 2015 Oct;70(10):2725-8
pubmed: 26169560
Clin Microbiol Rev. 2018 Aug 15;31(4):
pubmed: 30111577
J Clin Microbiol. 2016 Nov;54(11):2695-2700
pubmed: 27558182
Microb Drug Resist. 2019 Jun;25(5):739-743
pubmed: 30676886
Epidemiol Infect. 2014 Apr;142(4):812-9
pubmed: 23866831
Jundishapur J Microbiol. 2016 Feb 15;9(2):e30412
pubmed: 27127592
Antimicrob Agents Chemother. 2007 Apr;51(4):1228-33
pubmed: 17242142
Iran J Basic Med Sci. 2014 Aug;17(8):595-9
pubmed: 25422753
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Clin Microbiol. 2005 Sep;43(9):4704-7
pubmed: 16145130
Antimicrob Agents Chemother. 2005 Dec;49(12):5069-74
pubmed: 16304174
Eur J Clin Microbiol Infect Dis. 2016 Jun;35(6):927-33
pubmed: 26993288
Emerg Microbes Infect. 2019;8(1):2-7
pubmed: 30866792
Int J Antimicrob Agents. 2019 Mar;53(3):203-210
pubmed: 30414439
Clin Microbiol Rev. 1998 Jul;11(3):497-513
pubmed: 9665980
Antimicrob Agents Chemother. 2009 Jun;53(6):2650-3
pubmed: 19332682
Antimicrob Agents Chemother. 2015 Apr;59(4):2466-9
pubmed: 25666148
Clin Infect Dis. 2013 Sep;57(5):682-8
pubmed: 23845950
Clin Infect Dis. 2009 Jul 1;49(1):85-92
pubmed: 19480572
J Perinatol. 2013 Mar;33(3):198-205
pubmed: 22814941
J Infect Dis. 2014 Sep 15;210(6):982-91
pubmed: 24620021
MMWR Recomm Rep. 2010 Nov 19;59(RR-10):1-36
pubmed: 21088663